Iago Rodríguez–Lago
A5077137875- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Diverticular Disease and Complications
- Pregnancy and Medication Impact
- Celiac Disease Research and Management
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Gut microbiota and health
- Gastrointestinal disorders and treatments
- Mycobacterium research and diagnosis
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Esophageal and GI Pathology
- Systemic Lupus Erythematosus Research
- Pancreatitis Pathology and Treatment
- Ferroptosis and cancer prognosis
- Tuberculosis Research and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal Bleeding Diagnosis and Treatment
- Pharmaceutical studies and practices
- Liver Diseases and Immunity
Hospital de Galdakao
2016-2025
BioCruces Health research Institute
2019-2024
Universidad de Deusto
2021-2024
Hospital Universitari Germans Trias i Pujol
2024
Hospital General de Tomelloso
2021
Euskadiko Parke Teknologikoa
2021
Institute of Clinical and Experimental Medicine
2021
University of Rijeka
2020
Medical University of Vienna
2019
Universidad Autónoma de Madrid
2019
The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed compare the relative risk severe infections in children mothers with inflammatory bowel disease (IBD) who were exposed anti-TNFα utero that not drugs.Retrospective multicenter cohort study. Exposed cohort: from IBD receiving medication (with or without thiopurines) at any time 3 months before conception. Non-exposed treated agents thiopurines cumulative...
Since the first description of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection produced by this microorganism (COVID-19) has been confirmed in 1,469,544 individuals around world (www.healthmap.org/covid-19/). In Spain, case COVID-19 was reported on January 31, 2020, and currently there are 146,690 cases 14,555 deaths secondary to (Ministry Health, Consumer Affairs Social Welfare, April 7, 2020). Basque Country (Spain), 9452 subjects have a positive test for...
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing sustain long-term remission, yet many patients experience failure. Filgotinib (FIL), selective JAK1 inhibitor, has emerged as promising therapeutic agent in UC management with favorable outcomes clinical trials. This study aimed evaluate the real-world efficacy safety FIL moderate-to-severe UC. Methods We...
Abstract Background Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are complex conditions characterized by significant clinical, immunological, molecular, genetic, microbiological heterogeneity. Current therapeutic strategies, particularly biologics Janus kinase (JAK) inhibitors, effective for inducing clinical remission controlling inflammation. However, one-third of patients fail to respond these treatments, highlighting the need predictive...
This study was carried out to investigate the clinical and biochemical factors which might be of importance in predicting outcome patients with myxoedema coma. Eleven (ten female) aged 68.1+/-19.5 years attended our institution over a period 18 years.Glasgow APACHE II scores serum free thyroxine TSH were measured all on entry. Patients selected at random treated two different regimens l-thyroxine.Four died mortality rate being 36.4%. The coma entry had significantly higher rates than those...
Inflammatory bowel disease [IBD] is a complex chronic disorder with no clear aetiology and known cure. Despite recent advances in overall management improved therapeutics, patients IBD still experience substantial burden. Furthermore, as the incidence continues to increase developing areas of world, it expected that burden society will exert tremendous pressure on health care systems worldwide. Therefore, new strategies prevent global are urgently required. Data being progressively acquired...
Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. aim this study was analyze and safety treatment with a second third anti-TNF drug after intolerance or failure previous in inflammatory bowel disease (IBD) patients. Methods We included patients diagnosed IBD from ENEIDA registry who received prior agent. Results A total 1122 were included. In short term, remission achieved 55% anti-TNF. incidence loss response 19% per...
Abstract Background and Aims Clinical trials real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy safety profile. However, these data are scarcely available elderly patients. Therefore, we aim to assess the effectiveness of patients CD. Methods Elderly [>60 years old] from prospectively maintained ENEIDA registry treated due CD were included. Every patient was matched two controls under 60 age, according anti-tumour necrosis factor use smoking...
Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics management PSC IBD patients, factors malignancies. Methods patients were identified from Spanish ENEIDA registry GETECCU. Additional data collected using AEG-REDCap electronic capture...
Background There is limited evidence on the effectiveness of biological therapy in stricturing complications patients with Crohn’s disease. Aim The study aims to determine anti‐tumor necrosis factor (TNF) agents disease complicated symptomatic strictures. Methods In this multicentric and retrospective study, we included adult receiving their first anti‐TNF therapy, no previous history biological, endoscopic or surgical therapy. agent was defined as a composite outcome combining steroid‐free...
Structures of the principal 0-glycosides from major cell surface sialoglycoprotein (ASGP-1) MAT-B1 and MAT-Cl ascites sublines 13762 rat mammary adenocarcinoma have been determined.Oligosaccharitols were released by alkaline borohydride treatments ASGP-1 purified gel filtration, DEAE-Sephadex ion exchange chromatography, high performance liquid chromatography.On basis carbohydrate composition, methylation analysis, periodate oxidation, exoglycosidase digestion, five oligosaccharides mild...
Despite the increased use of rescue medical therapies for steroid refractory acute severe ulcerative colitis, mortality related to this entity still remains high. We aimed assess and morbidity colectomy their predictive factors in evaluate changes rates, complications, indications colectomy, therapy over time.We performed a multicenter observational study patients with colitis requiring admitted 23 Spanish hospitals included ENEIDA registry (GETECCU) from 1989 2014. Independent were assessed...
Abstract Background and Aims Inflammatory bowel disease (IBD) is a prevalent chronic noncurable associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling IBD etiopathogenesis the diagnosis prognosis therefore pivotal. We sought to determine distinctive signatures from different subgroups before treatment initiation. Methods Serum urine samples newly diagnosed treatment-naïve patients age sex-matched healthy control (HC) individuals were...
Primary non-response and secondary loss of response to anti-TNF agents are common in inflammatory bowel disease. Increasing drug concentrations correlated better clinical remission rates. Combination granulocyte–monocyte apheresis (GMA) with anti-tumor necrosis factor (TNF) could be an option these patients. The objective our study was perform vitro assay determine if the GMA device can lead infliximab (IFX) adsorption. A blood sample obtained from a healthy control. It incubated three IFX...
Abstract Background Crohn’s disease (CD) is a chronic and progressive condition with growing global prevalence, leading to potential bowel damage disability. Data on the clinical presentation, outcomes, treatment options in newly diagnosed CD patients Europe current era are essential guide physicians. The aim describe characteristics of contemporary European cohort recently patients. Methods Crohn's Disease Cohort (CROCO) an ongoing, multicenter, prospective study within last 12 months,...
Abstract Background Upadacitinib (UPA) has shown promising results in the pivotal trials, which require validation clinical practice. Primary aim:To assess durability of UPA treatment patients with ulcerative colitis (UC). Secondary aims:To short and long-term effectiveness, dose optimization response to dosage adjustments, impact extraintestinal manifestations (EIM) immunomediated diseases (IMIDs), tolerability UC a real-world setting Methods Adult who started for at least 8 weeks prior...
Abstract Background Factors influencing the exposure to targeted therapies (biologics/JAKi), intestinal resections and hospitalisations in newly diagnosed IBD patients have been scarcely studied. Aim: To identify predictive factors of biologics/JAKi, surgeries, within first five years patients. Methods Prospective, population-based nationwide registry. Adult with [Crohn’s disease (CD), ulcerative colitis (UC) or unclassified (IBD-U)] during 2017 17 Spanish regions were included. Patients who...
Abstract Background Anti-tumor necrosis factor(TNF)α are the first target therapies approved to treat ulcerative colitis(UC). Drugs with different mechanisms of action(MoA) have then entered market, but data on optimal management UC after failure 1-line anti-TNFα lacking. Methods The PODIUM study is a retrospective, observational comparing real-life effectiveness and safety 2-line vedolizumab(VDZ), ustekinumab (UST) JAK inhibitors(JAKi). Consecutive patients(pts) 1+ never exposed other MoA...
Abstract Background The addition of selective Janus kinase inhibitors (JAKi) –tofacitinib (TOFA), upadacitinib (UPA), and filgotinib (FILGO)– to the therapeutic arsenal for ulcerative colitis (UC) has provoked need comparative studies establish their positioning in clinical practice. Aim: To compare durability short- long-term effectiveness TOFA, UPA, FILGO UC, evaluate real-world safety. Methods Adult patients who started JAKi treatment UC (from April 2021) at least 8 weeks prior data...
Abstract Background Incidentally diagnosed inflammatory bowel disease (IBD) can be found in asymptomatic individuals undergoing endoscopic examinations performed for various reasons such as colorectal cancer (CRC) screening. We aimed to characterize the prevalence of incidental IBD non-diagnostic colonoscopy and describe its clinical characteristics, course, medium long-term outcomes. Methods Retrospective cohort study including all adults who underwent CRC screening or polyp surveillance...